Analysts on Wall Street project that Biogen Inc. (BIIB) will announce quarterly earnings of $3.45 per share in its forthcoming report, representing an increase of 17% year over year. Revenues are ...

The stock's fall snapped a two-day winning streak.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Wall Street trading got off to a mixed start early on Wednesday as share price losses at tech giants Alphabet and AMD put ...

Brightcove's deal is one of several large acquisitions of local technology companies expected to close in 2025. Those include Markforged, which is set to be acquired by Waltham's Nano Dimension, and ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...